ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2010
Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 46 citations in OpenAlex.
- Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Trial
- CD79A/CD40 intracellular domain uses a 4-1BB-like metabolic pathway driven by cholesterol biosynthesis.Journal for immunotherapy of cancer · 2026Article
- Fluvastatin Promotes Treg Cell Production in Allogeneic Immune Reaction and Suppresses Inflammatory Response.Immunity, inflammation and disease · 2025Article
- Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Elevated high-density lipoprotein levels following acute graft-versus-host disease onset: a potential link to T-cell dysfunction and increased relapse risk.Clinical & translational immunology · 2025Article
- Impact of Donor Statin Treatment on Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.Transplantation and cellular therapy · 2023Observational
- Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications.Frontiers in medicine · 2023Review
- Heart Transplant, Kawasaki Disease, and Bone Marrow Transplant: Are There Consequences?Current atherosclerosis reports · 2022Review
- Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation.Bone marrow transplantation · 2021Review
- Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD.Blood cancer journal · 2021Article
- Monogenic Immune Diseases Provide Insights Into the Mechanisms and Treatment of Chronic Graft-Versus-Host Disease.Frontiers in immunology · 2020Review
- Managing Endocrine Disorders in Adults After Hematopoietic Stem Cell Transplantation.Clinical hematology international · 2019Review
- Correlation of T Cell Subsets and Hypercholesterolemia of the Donor and Its Association with Acute Graft-versus-Host Disease.International journal of hematology-oncology and stem cell research · 2019Article
- Immune modulatory effects of statins.Immunology · 2018Review
- Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease.Current pathobiology reports · 2018Review
- Article
- Clinical use of statins in hematopoietic stem cell transplantation: Old drugs and new horizons.International journal of hematology-oncology and stem cell research · 2016Review
- Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation.International journal of hematologic oncology · 2015Article
- Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Review
- The association between donor and recipient statin use and infections after allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
We retrospectively analyzed outcomes among 1206 patients with hematologic malignancies who had hematopoietic cell transplantation (HCT) from HLA-identical siblings (n = 630) or HLA-matched unrelated donors (n = 576) at a single institution between 2001 and 2007 for a correlation between recipient statin use and risk of graft-versus-host disease (GVHD). Among recipients with cyclosporine-based postgrafting immunosuppression (n = 821), statin use at the time of transplant (6%) was associated with a decreased risk of extensive chronic GVHD (cGVHD) (multivariate hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.4-1.0; P = .05) and an increased risk of recurrent malignancy (HR, 1.75; 95% CI, 1.0-3.0; P = .04). Recipient statin use, however, had no apparent impact on the risks of cGVHD and recurrent malignancy among recipients given tacrolimus-based immunosuppression (n = 385; 8% statin treated). Risks of acute GVHD, nonrelapse mortality, and overall mortality were not significantly affected by recipient statin use. Hence, recipient statin treatment at the time of allogeneic HCT may decrease the risk of cGVHD in patients with cyclosporine-based immunosuppression, but at the expense of a compromised graft-versus-tumor effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.